Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TDS Pharm Co's Total Assets for the quarter that ended in Jun. 2026 was ₩63,713 Mil.
During the past 12 months, TDS Pharm Co's average Total Assets Growth Rate was 71.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 18.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 8.00% per year.
During the past 6 years, TDS Pharm Co's highest 3-Year average Total Assets Growth Rate was 18.20%. The lowest was -0.70%. And the median was -0.70%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
TDS Pharm Co's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
TDS Pharm Co Total Assets Related Terms
TDS Pharm Co Total Assets Historical Data
* Premium members only.
The historical data trend for TDS Pharm Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
TDS Pharm Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDS Pharm Co (XKRX:464280) has a Total Assets of ₩63,713 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on TDS Pharm Co and its competitors.
Is TDS Pharm Co's Total Assets too high?
TDS Pharm Co's current Total Assets is ₩63,713 Mil. Overall, TDS Pharm Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does TDS Pharm Co's Total Assets compare to LLY and JNJ?
TDS Pharm Co's Total Assets of ₩63,713 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on TDS Pharm Co and its competitors. TDS Pharm Co's current Total Assets is ₩63,713 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TDS Pharm Co stock overvalued right now?
TDS Pharm Co (XKRX:464280) has a current Total Assets of ₩63,713 Mil. The current Total Assets is ₩63,713 Mil. TDS Pharm Co's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For TDS Pharm Co (XKRX:464280), the current Total Assets is ₩63,713 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
40GF Score
Get the complete analysis for XKRX:464280
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:464280 has been successfully added to your 
